Mineralys Therapeutics (MLYS)
Develops lorundrostat for uncontrolled hypertension and related cardiorenal conditions.
$29.03
Pre-market−0.02 (−0.07%)
At close$29.05(+13.61%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions241 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 112.17% | 99.16M shares | |
| Insiders11 holders · as of Aug 25, 2026 | 8.83% | 7.81M shares | |
| Strategic holders1 holder · as of Mar 17, 2025 | 6.42% | 5.67M shares | |
| Adds to | 127.42% |
88.41M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 127.42%; nothing is left for Other.
Institutions13F, as of Jun 30, 2026
241 holders · 99.16M shares · 38 new positions · 122 increased · 71 reduced · 25 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Catalys Pacific, LLC | 7.90M | 8.94% | 0 | Aug 5, 2026 |
| Ra Capital Management, L.P. | 7.69M | 8.70% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 5.89M | 6.66% | +1.41M | Aug 7, 2026 |
| Samsara Biocapital, LLC | 5.87M | 6.64% | 0 | Aug 14, 2026 |
| FMR LLC | 4.51M | 5.10% | −349.4K | Aug 13, 2026 |
| State Street Corp | 4.14M | 4.68% | +1.21M | Aug 7, 2026 |
| Deerfield Management Company, L.P. (Series C) | 3.96M | 4.48% | +3.96Mnew | Aug 14, 2026 |
| Vanguard Capital Management LLC | 2.76M | 3.12% | +302.4K | Aug 13, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Catalys Pacific Fund, LP | 10.10% | 8.00M | 13G | Feb 13, 2026 ↗ |
| RA Capital Management, L.P.incl. Peter Kolchinsky, Rajeev Shah +1 more | 9.90% | 7.80M | 13D | Sep 8, 2025 ↗ |
| Srinivas Akkarajuincl. Samsara Opportunity Fund, L.P., Samsara Opportunity Fund GP, LLC +2 more | 8.20% | 6.35M | 13D | Sep 8, 2025 ↗ |
| FMR LLC | 6.30% | 5.02M | 13G | Feb 5, 2026 ↗ |
| BlackRock, Inc. | 5.20% | 4.11M | 13G | Jan 21, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 21, 2026 | Eric Warrenofficer: Chief Commercial Officer | Sale | 7,437 | $25.98 | 38,400 |
| Aug 10, 2026 | David Malcom Rodmanofficer: Chief Medical Officer | Sale | 2,170 | $27.09 | 51,384 |
| Jul 21, 2026 | Eric Warrenofficer: Chief Commercial Officer | Sale | 7,438 | $26.87 | 38,400 |
| Jul 17, 2026 | David Malcom Rodmanofficer: Chief Medical Officer | Sale | 416 | $26.53 | 51,384 |
| Jul 15, 2026 | David Malcom Rodmanofficer: Chief Medical Officer | Sale | 6,349 | $26.61 | 51,384 |
| Jul 13, 2026 | David Malcom Rodmanofficer: Chief Medical Officer | Sale | 14,058 | $27.58 | 57,733 |
| Jul 13, 2026 | Jon Congletondirector, officer: Chief Executive Officer | Sale | 10,700 | $27.24 | 603,621 |
| Jul 9, 2026 | David Malcom Rodmanofficer: Chief Medical Officer | Sale | 2,171 | $30.30 | 57,733 |
| Jun 26, 2026 | Eric Warrenofficer: Chief Commercial Officer | Sale | 104,124 | $25.90 | 38,400 |
| Jun 30, 2026 | Jon Congletondirector, officer: Chief Executive Officer | Sale · 2 lots | 75,000 | $26.14 | 614,321 |
CongressHouse and Senate disclosures
Not reported.